Phase I AZD2171 in patients with relapsed or refractory AML and Elderly patients with DeNovo or secondary AML

Study identifier:D8480C00002

ClinicalTrials.gov identifier:NCT00502385

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Medical condition

Leukaemia

Phase

Phase 1

Healthy volunteers

Study drug

AZD2171

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 30 Apr 2004

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2025 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

CSR-D8480C00002.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Information Study

1-800-236-9933

[email protected]

Investigators

Principal Investigator

Nick Botwood

AstraZeneca